Aarti Drugs’ API business gains as pharma firms diversify raw material sourcing from China – Moneycontrol

Company?s stock among those that gained substantially during COVID-19 days. Drug maker planning contract manufacturing of specialty products. Other Indian pharma companies also benefit as buyers, both domestic and global, scout for non-Chinese suppliers of ra? Read More